Search research articles
Contact Us
Filters
Showing results (131-140 of 276) with videos related to
Page
of 28
Sort By:
Nature Biotechnology
|
January 8, 2020
The therapeutic landscape for cells engineered with chimeric antigen receptors
Matthew MacKay, Ebrahim Afshinnekoo, Jonathan Rub, et al.
British Journal of Haematology
|
December 12, 2025
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial
Maria Teresa Voso, Stéphane de Botton, Michael Pfeilstöcker, et al.
Cancer Medicine
|
December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Rami S Komrokji, Najla H Al Ali, David Sallman, et al.
Leukemia & Lymphoma
|
March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)
Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Haematologica
|
September 28, 2019
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders
Farhad Ravandi, Iphigenia Koumenis, Anandhi Johri, et al.
Nature Medicine
|
July 11, 2018
Somatic mutations precede acute myeloid leukemia years before diagnosis
Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, et al.
Haematologica
|
March 23, 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
Andrew H Wei, Gail J Roboz, Herve Dombret, et al.
Blood Advances
|
July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
Jorge E Cortes, Jay Yang, Gail J Roboz, et al.
British Journal of Haematology
|
November 12, 2023
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001
Farhad Ravandi, Hartmut Döhner, Andrew H Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
Eric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Page
of 28
Search research articles
Search
Showing results (131-140 of 276) with videos related to
Sort By:
Page
of 28
Nature Biotechnology
|
January 8, 2020
The therapeutic landscape for cells engineered with chimeric antigen receptors
Matthew MacKay, Ebrahim Afshinnekoo, Jonathan Rub, et al.
British Journal of Haematology
|
December 12, 2025
Oral azacitidine maintenance therapy for patients with acute myeloid leukaemia and myelodysplasia-related changes: Post hoc analysis of the QUAZAR AML-001 trial
Maria Teresa Voso, Stéphane de Botton, Michael Pfeilstöcker, et al.
Cancer Medicine
|
December 22, 2020
Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
Rami S Komrokji, Najla H Al Ali, David Sallman, et al.
Leukemia & Lymphoma
|
March 28, 2024
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m<i>IDH1</i>) acute myeloid leukemia (AML)
Jorge Cortes, Brian A Jonas, Gary Schiller, et al.
Haematologica
|
September 28, 2019
Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders
Farhad Ravandi, Iphigenia Koumenis, Anandhi Johri, et al.
Nature Medicine
|
July 11, 2018
Somatic mutations precede acute myeloid leukemia years before diagnosis
Pinkal Desai, Nuria Mencia-Trinchant, Oleksandr Savenkov, et al.
Haematologica
|
March 23, 2023
Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
Andrew H Wei, Gail J Roboz, Herve Dombret, et al.
Blood Advances
|
July 16, 2025
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
Jorge E Cortes, Jay Yang, Gail J Roboz, et al.
British Journal of Haematology
|
November 12, 2023
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001
Farhad Ravandi, Hartmut Döhner, Andrew H Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia
Eric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Page
of 28